ARWR Share Price

Open 3.66 Change Price %
High 3.75 1 Day -0.01 -0.27
Low 3.57 1 Week 0.00 0.00
Close 3.64 1 Month -0.36 -9.00
Volume 241297 1 Year -0.54 -12.92
52 Week High 5.01
52 Week Low 1.20
ARWR Important Levels
Resistance 2 3.81
Resistance 1 3.74
Pivot 3.65
Support 1 3.54
Support 2 3.47
NASDAQ USA Most Active Stocks
YHOO 52.58 0.00%
YHOO 52.58 0.00%
YHOO 52.58 0.00%
FNFG 10.18 -0.20%
DELL 13.86 0.22%
RFMD 16.59 -2.07%
MU 44.31 6.39%
MU 44.31 6.39%
MU 44.31 6.39%
RIMM 13.03 0.39%
NASDAQ USA Top Gainers Stocks
LOCM 0.09 50.00%
SCHS 0.04 33.33%
BSDM 0.62 26.53%
SNTA 0.34 25.93%
HLIT 3.70 25.42%
OTT 2.39 25.13%
QNST 8.90 20.76%
VRTA 4.00 19.40%
SNSS 2.56 19.07%
GCFB 0.44 18.92%
NASDAQ USA Top Losers Stocks
TXCC 0.01 -95.00%
GMETP 0.15 -76.92%
HCIIP 10.10 -67.52%
CRMB 0.27 -57.81%
KIOR 0.03 -57.14%
OSH 0.26 -49.02%
OSH 0.26 -49.02%
DVOX 0.05 -44.44%
PRXI 0.21 -43.24%
TRGT 0.96 -41.46%

Arrowhead Research Corporation (NASDAQ: ARWR)

ARWR Technical Analysis 3
As on 31st Oct 2017 ARWR Share Price closed @ 3.64 and we RECOMMEND Buy for LONG-TERM with Stoploss of 2.14 & Buy for SHORT-TERM with Stoploss of 3.41 we also expect STOCK to react on Following IMPORTANT LEVELS.
ARWR Target for May
1st Target up-side 4.32
2nd Target up-side 4.79
3rd Target up-side 5.26
1st Target down-side 2.96
2nd Target down-side 2.49
3rd Target down-side 2.02
ARWR Other Details
Segment EQ
Market Capital 29295014.00
Sector Healthcare
Industry Biotechnology
Offical website
ARWR Address
225 South Lake Avenue
Suite 1050
Pasadena, CA 91101
United States
Phone: 626-304-3400
Fax: 626-304-3401
ARWR Latest News
Interactive Technical Analysis Chart Arrowhead Research Corporation ( ARWR NASDAQ USA )
Java support must be enabled in order to display FnCharts.
You can download Java from
Your Comments and Response on Arrowhead Research Corporation
ARWR Business Profile
Arrowhead Research Corporation (Arrowhead), incorporated in 1989, is a development-stage company. Arrowhead is a nanomedicine company engaged in development therapeutic products at the interface of biology and nano-engineering to cure disease and improve human health. Arrowhead is focused on the preclinical and clinical development of therapeutics for the treatment of cancer and obesity, as well as the regeneration of wounded or diseased tissue. Arrowhead’s portfolio includes Calando Pharmaceuticals, Inc. (Calando), delivers small ribonucleic acid (RNA) for gene silencing; and Ablaris Therapeutics, Inc. (Ablaris), an anti-obesity therapeutics company; Nanotope, Inc. (Nanotope), a regenerative medicine company and Leonardo (Leonardo), a multi-stage drug delivery company. In January 2011, the Company announced that its subsidiary, Unidym, Inc. has been acquired by Wisepower Co., Ltd. In October 2011, the Company acquired RNA therapeutics assets from Roche Holding Ltd. including the research site in Madison, WI. In April 2012, it acquired Alvos Therapeutics, Inc., formerly Mercator Therapeutics, Inc. Calando is a clinical stage nano-biotechnology company at the forefront of RNA interference (RNAi) therapeutics. Calando has developed a nanoparticle-based drug delivery system for siRNA. Calando’s platform technology is being used in a Phase-I clinical trial. Calando is focused on the clinical development of RONDELTM, its small interfering RNA (siRNA) delivery technology, and CALAA-01, the associated drug candidate. CALAA-01 is a combination of RONDEL and siRNA targeting the M2 subunit of ribonucleotide reductase. Ribonucleotide reductase catalyzes the conversion of ribonucleosides to deoxyribonucleosides and is used for deoxyribonucleic acid (DNA) synthesis and replication. The siRNA, developed at Calando, demonstrates anti-proliferative activity across multiple types of cancer cells. During the fiscal year ended September 30, 2010 (fiscal 2010), 18 patients were enrolled in the Phase-I clinical trial. Nanotope is a regenerative medicine company developing a suite of nanotechnology-based products customized to regenerate specific tissues, including neuronal, cartilaginous and vascular soft tissues. Its lead clinical candidates are focused on regenerating neurons and inhibiting scar tissue formation for traumatic spinal cord injury (SCI); restoring cartilage in joints damaged due to injury or osteoarthritis; and wound healing in vascularized, ischemic tissue associated with diabetes and peripheral artery disease (PAD).